



ASX ANNOUNCEMENT

Swine Influenza Vaccines

Imugene completes laboratory construction of swine influenza vaccines

27 July 2009, Sydney, Australia. Imugene has recently completed the construction of vaccines for two strains of Swine Influenza. Imugene has produced vaccines for the H1N1 and H3N2 strains. The vaccines have completed the laboratory construction phase and are ready to progress to animal trials for efficacy testing.

The commercial parameters of the Swine Influenza vaccines are now being evaluated. The vaccines will enter the product development program if commercial parameters are satisfied and the market deemed sufficiently large.

Imugene's Swine Influenza vaccine development program commenced in early 2008 and has identified both H1N1 and H3N2 vaccines as potential vaccines for development. Swine Influenza is a respiratory viral disease of pigs and outbreaks occur throughout many parts of the world. Vaccination against Swine Influenza is routine in many countries.

About Imugene

Imugene specialises in commercialising animal health products for production animals including pigs and poultry.

Imugene owns the worldwide rights to the *Fowl Adenoviral Vector Delivery System* for poultry and the *Porcine Adenoviral Vector Delivery System* for pigs. Since establishing a laboratory at La-Trobe University, Victoria, additional vaccine technology has been developed for the pig & poultry industries.

A Strategic Alliance with Merial Limited agreed in December 2008, provides the strength of Merial's vast experience and infrastructure to the development of Imugene's innovative range of vaccine candidates. In return for exclusivity over the Imugene technology, Imugene will receive annual payments, milestone fees and royalties.

Imugene's poultry and pig vaccine portfolio is targeting a worldwide US\$3 billion annual market with several lead vaccine products under development and a strong product pipeline. Consumer demands for disease free and residue free food will bolster Imugene's prospects.

For more information please visit the Imugene Website www.imugene.com or contact:

Dr Warwick Lamb
Managing Director
+61 2 9870 7330

Mr Graham Dowland
Executive Chairman
+61 8 9440 2660

ABN 99 009 179 551

Registered Office
Level 20, Allendale Square, 77 St Georges Terrace, Perth WA 6000
Tel +61 8 94402660 Fax +61 8 9 4402699

www.imugene.com